Health News

Rx Combo Slowed Multiple Myeloma
When it comes to treating multiple myeloma, three medications may be better than two.
Personalizing Blood Cancer Treatment
Huge advances have been made in the understanding of multiple myeloma. There are a variety of approaches for treating this blood cancer. The trick is to provide what’s best for the individual patient.
Closing In on a Cure
Someone diagnosed with any type of leukemia in the early 1960s had about a 14 percent chance of being alive five years later. Today, those chances are vastly greater. 
New Rx for Advanced Multiple Myeloma
Multiple myeloma is a blood cancer that affects nearly 22,000 Americans every year. It develops in mostly older people when plasma cells in the bone marrow grow out of control.
Stronger Blood Cancer Drug Appears Successful
Part of the treatment for especially severe cancers of the blood is to destroy all the cells in the bone marrow that are responsible for making both the good and bad parts of the blood with radiation therapy.
Revlimid and Risk of New Cancers
The U.S. Food and Drug Administration (FDA) is informing the public of an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received Revlimid ( lenalidomide ).
Cancer Rx Linked to Second Cancers
Health Canada, the Canadian version of the U.S. Food & Drug Administration (FDA), has issued an alert regarding the medication  REVLIMID ( lenalidomide ) that's used to treat multiple myeloma .
Keys to Unlocking Multiple Myeloma Resistance
People living with the blood cancer multiple myeloma typically take two drugs in combination. The problem is these drugs don't work with every person and tend to fade in effectiveness over time.
FDA Drug Safety Communication: Revlimid
The U.S. Food and Drug Administration (FDA) is informing the public that we are aware of results from clinical trials conducted inside and outside the United States that found that patients treated with Revlimid ( lenalidomide ) may be at an increased risk of developing new types of cancer compared to patients who did not take the drug. FDA is currently reviewing all available information on this potential risk and will communicate any new recommendations once it has completed its review. At this time, FDA recommends that patients continue their Revlimid treatment as prescribed by their...
New Hope for Multiple Myeloma Patients
While there is no cure for multiple myeloma, a form of blood cancer, new therapy offers hope for keeping the disease from progressing. When used as a maintenance or ongoing therapy, Revlimid (lenalidomide) delays the progression of multiple myeloma and improves overall survival of newly diagnosed patients who have had a stem-cell transplant.